Remifentanil
- Generic Name
- Remifentanil
- Brand Names
- Ultiva
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5
- CAS Number
- 132875-61-7
- Unique Ingredient Identifier
- P10582JYYK
- Background
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
- Indication
For use during the induction and maintenance of general anesthesia.
- Associated Conditions
- -
- Associated Therapies
- Immediate postoperative analgesia therapy, Induction and Maintenance of General Anesthesia, Monitored anesthesia care sedation
The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2009-11-18
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 24
- Registration Number
- NCT00811837
- Locations
- 🇦🇹
Department of Anaesthesia, Medical University of Vienna, Vienna, Austria
Intravenous Remifentanil Patient-controlled Analgesia (PCA) and Epidural Patient Controlled Epidural Analgesia (PCEA) for Labor Analgesia
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 50
- Registration Number
- NCT00801047
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
The Effect of Remifentanil on Established Capsaicin-Induced Hyperalgesia in Human Volunteers
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2009-05-21
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 24
- Registration Number
- NCT00789386
- Locations
- 🇦🇹
Department of Anaesthesia, Medical University of Vienna, Vienna, Austria
Modulation of Remifentanil-induced Postinfusion Hyperalgesia
- Conditions
- Interventions
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2011-07-01
- Lead Sponsor
- Ullevaal University Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT00785863
- Locations
- 🇳🇴
Ullevaal University Hospital, Oslo, Norway
Use of Closed-loop Anesthesia in Pediatric Patients
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Hopital Foch
- Target Recruit Count
- 45
- Registration Number
- NCT00778505
- Locations
- 🇫🇷
Hôpital Foch, Suresnes, France
🇫🇷Hôpital Necker Enfants, Paris, France
Influence of Intraoperative Analgesia on the Postoperative Morphine Consumption
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Hopital Foch
- Target Recruit Count
- 60
- Registration Number
- NCT00772616
- Locations
- 🇫🇷
Hopital Foch, Suresnes, France
Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery.
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2013-09-12
- Lead Sponsor
- Kuopio University Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT00757198
- Locations
- 🇫🇮
Kuopio University hospital, Kuopio, Finland
Intravenous Remifentanil for Labor Analgesia
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Nanjing Medical University
- Target Recruit Count
- 1000
- Registration Number
- NCT00710086
- Locations
- 🇨🇳
Nanjing Maternal and Child Health Care Hospital, Nanjing, Jiangsu, China
Effect of Total Intravenous Anesthesia and Balanced Anesthesia on Postoperative Lung Function
- Conditions
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2009-02-10
- Lead Sponsor
- Medical University Innsbruck
- Target Recruit Count
- 60
- Registration Number
- NCT00706277
- Locations
- 🇦🇹
TILAK Hospitals, Innsbruck, Austria
Effect of Spinal Ketorolac After Acute Opioid Exposure
- Conditions
- Interventions
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 30
- Registration Number
- NCT00693160
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.